eLife (Feb 2021)

The allosteric modulation of complement C5 by knob domain peptides

  • Alex Macpherson,
  • Maisem Laabei,
  • Zainab Ahdash,
  • Melissa A Graewert,
  • James R Birtley,
  • Monika-Sarah ED Schulze,
  • Susan Crennell,
  • Sarah A Robinson,
  • Ben Holmes,
  • Vladas Oleinikovas,
  • Per H Nilsson,
  • James Snowden,
  • Victoria Ellis,
  • Tom Eirik Mollnes,
  • Charlotte M Deane,
  • Dmitri Svergun,
  • Alastair DG Lawson,
  • Jean MH van den Elsen

DOI
https://doi.org/10.7554/eLife.63586
Journal volume & issue
Vol. 10

Abstract

Read online

Bovines have evolved a subset of antibodies with ultra-long heavy chain complementarity determining regions that harbour cysteine-rich knob domains. To produce high-affinity peptides, we previously isolated autonomous 3–6 kDa knob domains from bovine antibodies. Here, we show that binding of four knob domain peptides elicits a range of effects on the clinically validated drug target complement C5. Allosteric mechanisms predominated, with one peptide selectively inhibiting C5 cleavage by the alternative pathway C5 convertase, revealing a targetable mechanistic difference between the classical and alternative pathway C5 convertases. Taking a hybrid biophysical approach, we present C5-knob domain co-crystal structures and, by solution methods, observed allosteric effects propagating >50 Å from the binding sites. This study expands the therapeutic scope of C5, presents new inhibitors, and introduces knob domains as new, low molecular weight antibody fragments, with therapeutic potential.

Keywords